Navin Fluorine International reported a 108% year-on-year increase in consolidated net profit for Q1FY27, reaching ₹243.31 crore. The surge was underpinned by robust operational performance, with revenue from operations climbing 44% YoY to ₹1,045.08 crore.

Operating EBITDA expanded significantly to ₹357.07 crore, reflecting a 73% YoY growth. This resulted in an operating EBITDA margin of 34.2%, marking a substantial expansion of 566 basis points compared to the same period last year. The company attributed the strong top-line growth to volume increases and favorable pricing environments across its key business verticals.

Segment Performance Highlights

The company’s three primary business verticals demonstrated varying degrees of growth momentum during the quarter:

• CDMO: Revenue surged 82% YoY to ₹180 crore, driven by increased demand from a European major and expanding footprint in their supply chain.
• Specialty Chemicals: Revenue rose 48% YoY to ₹325 crore, supported by strong order visibility and product pipeline scale-up.
• High Performance Products (HPP): Revenue grew 33% YoY to ₹540 crore, led by volume growth and higher realizations in refrigerants.

What the Numbers Show

A notable divergence exists between revenue growth and profitability expansion. While revenue grew 44% YoY, operating PBT doubled with a 101% YoY increase. This indicates significant operating leverage, as fixed costs were absorbed more efficiently against higher sales volumes. Furthermore, other income contributed ₹35.09 crore to the bottom line, representing approximately 12% of the total profit before tax, highlighting a growing contribution from non-operational sources alongside core business strength.

Capital Expenditure and Future Outlook

The company announced new capital expenditure plans to support future growth. A capex of ₹90 crore is allocated for advanced materials adoption capacities, targeted for completion by Q2FY28. Additionally, Phase II of the cGMP4 facility involves a capex of ₹125 crore, expected to be operational by Q4FY27 to meet increasing demand from global partners.

Discussions at the upcoming analyst meeting will focus on these publicly available figures and strategic initiatives.

Navin Fluorine International announced that its wholly owned subsidiary, Navin Fluorine Advanced Sciences Limited (NFASL), has commenced commercial production and dispatch at its Dahej facility.

Production milestone at Dahej

The company confirmed that NFASL successfully commissioned the debottlenecking capacity for the Multi Purpose Plant (MPP) facility at the Dahej site. Commercial production and dispatch of the product started on September 29, 2026. This development follows the Board's earlier approval in October 2025 to fund ₹75 crore for the debottlenecking exercise.

Debottlenecking typically refers to process optimisation efforts aimed at removing capacity constraints within an existing facility, enabling higher output without constructing an entirely new plant. The commencement of commercial production signals that these efforts are complete and the plant is operational at its enhanced capacity.

The Dahej facility is part of Navin Fluorine International's manufacturing infrastructure. The update clarifies that the operational entity is NFASL, a wholly owned subsidiary, rather than the parent company directly operating the line.